SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Telix Joins Thera4Care for Phase 1 Cancer Therapy Trial

Telix is joining Thera4Care for a Phase 1 trial of a terbium-161 FAP-targeting cancer therapy.

Related stories